Individual domain scores of the AE‐QoL were improved for berotralstat‐treated patients but were not statistically different from placebo, with the exception of 1 domain (fears/shame), where patients in the 150 mg group experienced a nominally significant improvement (Figure 3 ).
← all excerpts
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
1
—
—